Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.
Luckily for you, we at StockStory have no conflicts of interest - our sole job is to help you find genuinely promising companies. That said, here is one stock where Wall Street’s excitement appears well-founded and two where analysts may be overlooking some important risks.
Two Stocks to Sell:
UiPath (PATH)
Consensus Price Target: $15.93 (43.1% implied return)
Starting with robotic process automation (RPA) and evolving into a comprehensive automation powerhouse, UiPath (NYSE: PATH) provides an AI-powered business automation platform that enables organizations to create software robots that mimic human actions to streamline repetitive tasks and processes.
Why Do We Think Twice About PATH?
- Sales trends were unexciting over the last two years as its 13.2% annual growth was below the typical software company
- Average billings growth of 2.3% over the last year was subpar, suggesting it struggled to push its software and might have to lower prices to stimulate demand
- Estimated sales growth of 9.4% for the next 12 months implies demand will slow from its two-year trend
At $11.13 per share, UiPath trades at 3.5x forward price-to-sales. Dive into our free research report to see why there are better opportunities than PATH.
Agilent (A)
Consensus Price Target: $161.72 (34.2% implied return)
Originally spun off from Hewlett-Packard in 1999 as its measurement and analytical division, Agilent Technologies (NYSE: A) provides analytical instruments, software, services, and consumables for laboratory workflows in life sciences, diagnostics, and applied chemical markets.
Why Does A Fall Short?
- 2.4% annual revenue growth over the last two years was slower than its healthcare peers
- Organic sales performance over the past two years indicates the company may need to make strategic adjustments or rely on M&A to catalyze faster growth
- Capital intensity has ramped up over the last five years as its free cash flow margin decreased by 5.8 percentage points
Agilent is trading at $120.53 per share, or 19.7x forward P/E. Read our free research report to see why you should think twice about including A in your portfolio.
One Stock to Watch:
Accenture (ACN)
Consensus Price Target: $288.63 (36.9% implied return)
With a workforce of approximately 774,000 people serving clients in more than 120 countries, Accenture (NYSE: ACN) is a professional services firm that helps organizations transform their businesses through consulting, technology, operations, and digital services.
Why Do We Like ACN?
- Annual revenue growth of 9.6% over the last five years was superb and indicates its market share increased during this cycle
- Enormous revenue base of $70.73 billion provides significant distribution advantages
- Market-beating returns on capital illustrate that management has a knack for investing in profitable ventures
Accenture’s stock price of $210.82 implies a valuation ratio of 15.1x forward P/E. Is now a good time to buy? See for yourself in our in-depth research report, it’s free.
High-Quality Stocks for All Market Conditions
ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.
Find out which 5 stocks it's flagging for this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.
